Drug makers are doing everything to tap the bottomless well of demand for new obesity drugs — and now, they might get some government help. CMS is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans, John Wilkerson writes.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,